New Clinical Trial Reveals Minimally Invasive Valve Procedure Significantly Reduces Mortality for High Risk Heart Patients

ACC.26 trial shows transcatheter mitral valve-in-valve procedures reduce death and stroke risk by 75% compared to open-heart redo surgery.

By: AXL Media

Published: Mar 30, 2026, 3:57 AM EDT

Source: Information for this report was sourced from American College of Cardiology

A Breakthrough in Managing Deteriorating Bioprosthetic Heart Valves

The medical community is witnessing a potential shift in the standard of care for patients facing the failure of previously implanted heart valves. According to Dimytri Siqueira, chief of interventions at the Dante Pazzanese Institute of Cardiology, a minimally invasive approach that inserts a new valve within the old one significantly outperforms traditional repeat surgery in the short term. The SURVIV trial specifically addressed the mitral valve, a critical component of heart function that often requires intervention due to tissue deterioration over time. By utilizing a catheter-based delivery system, surgeons can now bypass the high risks associated with opening the chest for a second or third time, providing a lifeline for those deemed too fragile for conventional methods.

The Rising Clinical Challenge of Redo Mitral Valve Surgery

As more patients opt for bioprosthetic valves made of animal tissue to avoid lifelong anticoagulation therapy, the healthcare system is seeing an influx of patients requiring secondary replacements. These biological valves typically last about a decade before they begin to degrade, often leaving patients in their 70s or 80s in need of another procedure. Research indicates that while initial valve surgeries carry a mortality rate of less than 1%, subsequent "redo" operations see that risk climb to approximately 7%. This escalation in danger is driven by the accumulation of scar tissue, older age, and comorbid conditions, making the development of a less traumatic alternative a high priority for interventional cardiologists worldwide.

Analyzing the Dramatic Survival Gap in the SURVIV Trial

The data from the 150-patient study conducted in Brazil revealed a stark contrast in safety between the two surgical paths. At the one-year mark, the composite endpoint of death or disabling stroke occurred in 20.8% of patients who underwent traditional open-heart surgery, while only 5.3% of those treated with the transcatheter valve-in-valve method faced similar outcomes. Siqueira noted that this gap was primarily established in the immediate postoperative phase, where the invasiveness of surgery often led to complications that the catheter-based group avoided. In fact, in-hospital mortality was recorded at 12.5% for the surgical group, compared to a remarkable 0% for th...